Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Mol Sci ; 23(9)2022 May 05.
Artículo en Inglés | MEDLINE | ID: mdl-35563553

RESUMEN

Immunotherapy has become increasingly important in the treatment of colorectal cancer (CRC). Currently, CD73, also known as ecto-5'-nucleotidase (NT5E), has gained considerable interest as a potential therapeutic target. CD73 is one of the key enzymes catalyzing the conversion of extracellular ATP into adenosine, which in turn exerts potent immune suppressive effects. However, the role of CD73 expression on various cell types within the CRC tumor microenvironment remains unresolved. The expression of CD73 on various cell types has been described recently, but the role of CD73 on B-cells in CRC remains unclear. Therefore, we analyzed CD73 on B-cells, especially on tumor-infiltrating B-cells, in paired tumor and adjacent normal tissue samples from 62 eligible CRC patients. The highest expression of CD73 on tumor-infiltrating B-cells was identified on class-switched memory B-cells, followed by naive B-cells, whereas no CD73 expression was observed on plasmablasts. Clinicopathological correlation analysis revealed that higher CD73+ B-cells infiltration in the CRC tumors was associated with better overall survival. Moreover, metastasized patients showed a significantly decreased number of tumor-infiltrating CD73+ B-cells. Finally, neoadjuvant therapy correlated with reduced CD73+ B-cell numbers and CD73 expression on B-cells in the CRC tumors. As promising new immune therapies are being developed, the role of CD73+ B-cells and their subsets in the development of colorectal cancer should be further explored to find new therapeutic options.


Asunto(s)
5'-Nucleotidasa , Neoplasias Colorrectales , 5'-Nucleotidasa/metabolismo , Antígenos CD20 , Recuento de Células , Humanos , Inmunoterapia , Microambiente Tumoral
2.
Drug Des Devel Ther ; 15: 997-1011, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33727792

RESUMEN

BACKGROUND: T cells are important regulators of inflammation and, via release of mediators, can contribute to pulmonary fibrosis. Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease (ILD) and chronic fibrosing ILDs with a progressive phenotype. However, how nintedanib targets T cells has not been elucidated. MATERIALS AND METHODS: We investigated the immunomodulatory effects of nintedanib on T cells and peripheral blood mononuclear cells isolated from healthy donors. Cells were pre-incubated with different concentrations of nintedanib and then stimulated for 24 hours with anti-CD3 with or without anti-CD28 and with or without different cytokines. Levels of interferon gamma (IFN-γ), interleukin (IL)-2, IL-4, IL-5, IL-10, IL-12p70 and IL-13 were quantitated. Western blotting with primary antibodies against phospho-Lck-Y394, phospho-Lck-Y505, Lck-total and Cofilin examined the phosphorylation level of the Lck protein. In vitro T-cell proliferation, T-cell clustering and different T-cell populations were also assessed. RESULTS: Nintedanib blocked T-cell activation through inhibiting Lck-Y394 phosphorylation. Pretreatment of T cells with nintedanib reduced cluster formation as a marker of activation and inhibited the release of IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12p70 and IL-13 at clinically relevant concentrations ranging from 5-77 nmol/L. Nintedanib did not alter T-cell proliferation or numbers of CD4+ and CD8+ T cells, but did increase stimulated Th17-like cells without increasing IL-17A levels. CONCLUSION: These immunomodulatory effects may further explain how nintedanib slows the progression of pulmonary fibrosis in various ILDs.


Asunto(s)
Factores Inmunológicos/farmacología , Indoles/farmacología , Linfocitos T/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Citocinas/antagonistas & inhibidores , Citocinas/inmunología , Relación Dosis-Respuesta a Droga , Humanos , Relación Estructura-Actividad , Linfocitos T/inmunología
3.
J Exp Med ; 214(7): 2059-2071, 2017 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-28566276

RESUMEN

The role of AP-1 transcription factors in early B cell development and function is still incompletely characterized. Here we address the role of Fra-2 in B cell differentiation. Deletion of Fra-2 leads to impaired B cell proliferation in the bone marrow. In addition, IL-7-stimulated pro-B cell cultures revealed a reduced differentiation from large pre-B cells to small B cells and immature B cells. Gene profiling and chromatin immunoprecipitation sequencing analyses unraveled a transcriptional reduction of the transcription factors Foxo1, Irf4, Ikaros, and Aiolos in Fra-2-deficient B cells. Moreover, expression of IL7Rα and Rag 1/2, downstream targets of Irf4 and Foxo1, were also reduced in the absence of Fra-2. Pro-B cell proliferation and small pre-B cell differentiation were fully rescued by expression of Foxo1 and Irf4 in Fra-2-deficient pro-B cells. Hence, Fra-2 is a key upstream regulator of Foxo1 and Irf4 expression and influences proliferation and differentiation of B cells at multiple stages.


Asunto(s)
Linfocitos B/metabolismo , Proteína Forkhead Box O1/genética , Antígeno 2 Relacionado con Fos/genética , Factores Reguladores del Interferón/genética , Animales , Western Blotting , Diferenciación Celular/genética , Proliferación Celular/genética , Células Cultivadas , Femenino , Proteína Forkhead Box O1/metabolismo , Antígeno 2 Relacionado con Fos/metabolismo , Perfilación de la Expresión Génica/métodos , Factor de Transcripción Ikaros/genética , Factor de Transcripción Ikaros/metabolismo , Factores Reguladores del Interferón/metabolismo , Interleucina-7/farmacología , Masculino , Ratones de la Cepa 129 , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Células Precursoras de Linfocitos B/efectos de los fármacos , Células Precursoras de Linfocitos B/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transactivadores/genética , Transactivadores/metabolismo
4.
Arthritis Rheumatol ; 68(1): 138-51, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26361381

RESUMEN

OBJECTIVE: To determine whether overexpression of the activator protein 1 (AP-1) transcription factor Fra-1 in adipose-derived stromal cells (ADSCs) is an effective treatment of collagenase-induced osteoarthritis (OA). METHODS: OA was induced by injection of collagenase into the knee joints of male C57BL/6 mice. ADSCs were isolated from the inguinal fat pads of 8-week-old wild-type or Fra-1-transgenic mice and injected into the knee joints of mice with collagenase-induced OA 7 days after OA induction. Histologic analyses of cartilage destruction and chondrocyte cell death were performed. Adipogenic differentiation capacity was evaluated, gene expression was analyzed, and cytokine profiling was performed in stromal vascular fractions (SVFs) and ADSCs. RESULTS: OA-related cartilage destruction and chondrocyte cell death were significantly reduced in mouse knee joints treated with ADSCs from Fra-1-transgenic mice compared to mouse knee joints treated with ADSCs from wild-type mice. This effect did not result from the higher number of adipogenic progenitors observed in SVFs from Fra-1-transgenic compared to wild-type mouse fat pads, since injection of wild-type mouse ADSCs enriched for adipogenic progenitors did not show any additional chondroprotective effects compared to nonsorted ADSCs. However, Fra-1-transgenic mouse ADSCs showed decreased adipogenic differentiation capacity. Moreover, Fra-1 significantly inhibited proinflammatory interleukin-6 and pentraxin 3 expression, while increasing the expression of extracellular matrix proteins, such as periostin and spondin 1. These findings suggest that Fra-1 overexpression leads to an increased chondroprotective effect of ADSCs in OA. CONCLUSION: ADSCs overexpressing Fra-1 effectively protect against OA. Our data indicate that genetic modifications of ADSCs, such as Fra-1 overexpression, may improve their potential to protect articular cartilage against OA-mediated damage.


Asunto(s)
Artritis Experimental/genética , Artritis Experimental/prevención & control , Osteoartritis/genética , Proteínas Proto-Oncogénicas c-fos/genética , Rodilla de Cuadrúpedos/metabolismo , Células del Estroma/metabolismo , Adipogénesis/genética , Tejido Adiposo/citología , Tejido Adiposo/metabolismo , Animales , Artritis Experimental/inmunología , Artritis Experimental/metabolismo , Proteína C-Reactiva/inmunología , Proteína C-Reactiva/metabolismo , Cartílago Articular , Diferenciación Celular , Condrocitos/metabolismo , Colagenasas , Citocinas/inmunología , Perfilación de la Expresión Génica , Interleucina-6/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Proteínas del Tejido Nervioso/inmunología , Proteínas del Tejido Nervioso/metabolismo , Osteoartritis/inmunología , Osteoartritis/metabolismo , Proteínas Proto-Oncogénicas c-fos/inmunología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Rodilla de Cuadrúpedos/patología , Células del Estroma/citología , Células del Estroma/inmunología
5.
J Endocrinol ; 214(3): 409-19, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22707376

RESUMEN

In teleosts fish, secretion of GH is regulated by several hypothalamic factors that are influenced by the physiological state of the animal. There is an interaction between immune and endocrine systems through hormones and cytokines. GH in fish is involved in many physiological processes that are not overtly growth related, such as saltwater osmoregulation, antifreeze synthesis, and the regulation of sexual maturation and immune functions. This study was conducted to characterize a decapeptide compound A233 (GKFDLSPEHQ) designed by molecular modeling to evaluate its function as a GH secretagogue (GHS). In pituitary cell culture, the peptide A233 induces GH secretion and it is also able to increase superoxide production in tilapia head-kidney leukocyte cultures. This effect is blocked by preincubation with the GHS receptor antagonist [d-Lys(3)]-GHRP6. Immunoneutralization of GH by addition of anti-tilapia GH monoclonal antibody blocked the stimulatory effect of A233 on superoxide production. These experiments propose a GH-mediated mechanism for the action of A233. The in vivo biological action of the decapeptide was also demonstrated for growth stimulation in goldfish and tilapia larvae (P<0.001). Superoxide dismutase levels, antiprotease activity, and lectin titer were enhanced in tilapia larvae treated with this novel molecule. The decapeptide A233 designed by molecular modeling is able to function as a GHS in teleosts and enhance parameters of the innate immune system in the fish larvae.


Asunto(s)
Carpa Dorada/crecimiento & desarrollo , Hormona del Crecimiento/metabolismo , Inmunidad Innata/efectos de los fármacos , Oligopéptidos/farmacología , Tilapia/crecimiento & desarrollo , Animales , Acuicultura/métodos , Bioensayo , Células Cultivadas , Carpa Dorada/inmunología , Inmunidad Innata/inmunología , Modelos Moleculares , Oligopéptidos/síntesis química , Oligopéptidos/metabolismo , Hormonas Peptídicas/farmacología , Hipófisis/citología , Superóxido Dismutasa/metabolismo , Superóxidos/metabolismo , Tilapia/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...